Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRD137
MIFTS: 48

Cardiogenic Shock

Categories: Blood diseases, Cardiovascular diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cardiogenic Shock

About this section

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock 58 62 32
Shock, Cardiogenic 71
Shock Cardiogenic 54

Characteristics:

Orphanet epidemiological data:

58
cardiogenic shock
Prevalence: 1-5/10000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33


External Ids:

ICD10 32 R57.0
ICD10 via Orphanet 33 R57.0
UMLS via Orphanet 72 C0036980
Orphanet 58 ORPHA97292
UMLS 71 C0036980
Sources

Summaries for Cardiogenic Shock

About this section
PubMed Health : 62 About cardiogenic shock: Cardiogenic (kar-dee-oh-JE-nik) shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away. The most common cause of cardiogenic shock is damage to the heart muscle from a severe heart attack. However, not everyone who has a heart attack has cardiogenic shock. In fact, on average, only about 7 percent of people who have heart attacks develop the condition. If cardiogenic shock does occur, it's very dangerous. When people die from heart attacks in hospitals, cardiogenic shock is the most common cause of death.

MalaCards based summary : Cardiogenic Shock, also known as shock, cardiogenic, is related to cardiac tamponade and mitral valve insufficiency, and has symptoms including syncope and shock without mention of trauma. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Folate Metabolism and amb2 Integrin signaling. The drugs Dalteparin and Enoxaparin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and liver.

Wikipedia : 74 Cardiogenic shock (CS) is a medical emergency resulting from inadequate blood flow due to the... more...

Sources

Related Diseases for Cardiogenic Shock

About this section

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 cardiac tamponade 32.2 PLAT NPPB CRP
2 mitral valve insufficiency 31.3 NPPB CRP
3 inferior myocardial infarction 31.1 PLAT NPPB
4 myocardial infarction 30.8 PLAT NPPB IL6 CRP ADM
5 anterolateral myocardial infarction 30.8 PLAT NPPB
6 aortic valve insufficiency 30.8 NPPB CRP
7 mitral valve stenosis 30.6 NPPB CRP
8 cardiac rupture 30.5 PLAT CRP
9 tricuspid valve insufficiency 30.5 NPPB CRP
10 pulmonary embolism 30.3 PLAT NPPB CRP
11 limb ischemia 30.3 PLAT IL6
12 left bundle branch hemiblock 30.3 NPPB CRP
13 acute myocarditis 30.0 NPPB IL6 CRP
14 infective endocarditis 30.0 IL6 CRP
15 malignant hypertension 30.0 NPPB ADM
16 renovascular hypertension 29.9 NPPB ADM
17 renal hypertension 29.9 NPPB ADM
18 chronic thromboembolic pulmonary hypertension 29.9 NPPB CRP
19 constrictive pericarditis 29.9 NPPB CRP
20 acute myocardial infarction 29.9 PLAT NPPB IL6 CRP ADM
21 coronary stenosis 29.8 NPPB IL6 CRP
22 intermediate coronary syndrome 29.8 PLAT IL6 CRP
23 congestive heart failure 29.8 NPPB IL6 CRP ADM
24 endocarditis 29.8 PLAT IL6 CRP
25 atrial heart septal defect 29.8 PLAT NPPB CRP
26 peripheral vascular disease 29.7 PLAT IL6 CRP
27 systolic heart failure 29.7 NPPB IL6 CRP
28 exanthem 29.7 IL6 CRP
29 aortic aneurysm, familial abdominal, 1 29.6 IL6 CRP
30 pericardial effusion 29.6 NPPB IL6 CRP
31 respiratory failure 29.6 NPPB IL6 CRP ADM
32 leptospirosis 29.6 IL6 CRP
33 patent ductus arteriosus 1 29.6 NPPB CRP
34 capillary leak syndrome 29.6 IL6 ADM
35 patent foramen ovale 29.5 PLAT NPPB CRP
36 purpura 29.5 IL6 CRP
37 generalized atherosclerosis 29.5 IL6 CRP
38 compartment syndrome 29.5 IL6 CRP
39 bronchopneumonia 29.5 IL6 CRP
40 necrotizing fasciitis 29.5 IL6 CRP
41 endophthalmitis 29.4 IL6 CRP
42 peripheral artery disease 29.4 NPPB IL6 CRP
43 disseminated intravascular coagulation 29.4 PLAT IL6 CRP
44 panuveitis 29.4 IL6 CRP
45 dilated cardiomyopathy 29.4 NPPB IL6 CRP ADM
46 pharyngitis 29.4 IL6 CRP
47 pericarditis 29.3 NPPB IL6 CRP
48 acute cystitis 29.3 IL6 CRP
49 amyloidosis 29.3 NPPB IL6 CRP
50 brucellosis 29.3 IL6 CRP

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Intermediate Coronary Syndrome Kidney Disease
Mitral Valve Disease Peripheral Vascular Disease
Respiratory Failure Third-Degree Atrioventricular Block
Tricuspid Valve Disease Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:



Diseases related to Cardiogenic Shock
Sources

Symptoms & Phenotypes for Cardiogenic Shock

About this section

UMLS symptoms related to Cardiogenic Shock:


syncope, shock without mention of trauma
Sources

Drugs & Therapeutics for Cardiogenic Shock

About this section

PubMed Health treatment related to Cardiogenic Shock: 62

Cardiogenic shock is life threatening and requires emergency medical treatment . The condition usually is diagnosed after a person has been admitted to a hospital for a heart attack . If the person isn't already in a hospital, emergency treatment can start as soon as medical personnel arrive. The first goal of emergency treatment for cardiogenic shock is to improve the flow of blood and oxygen to the body’s organs . Sometimes both the shock and its cause are treated at the same time. For example, doctors may quickly open a blocked blood vessel that's damaging the heart . Often, this can get the patient out of shock with little or no additional treatment .

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Enoxaparin Approved Phase 4 9005-49-6 772
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
8
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
9
Racepinephrine Approved Phase 4 329-65-7 838
10
Abciximab Approved Phase 4 143653-53-6
11
Probucol Approved, Investigational Phase 4 23288-49-5 4912
12
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
13
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
16
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
17
Streptokinase Approved, Investigational Phase 4 9002-01-1
18
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
19
Atorvastatin Approved Phase 4 134523-00-5 60823
20
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
21
Dobutamine Approved Phase 4 34368-04-2 36811
22
Norepinephrine Approved Phase 4 51-41-2 439260
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
tannic acid Approved Phase 4 1401-55-4
25
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
26
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
27
Ticagrelor Approved Phase 4 274693-27-5 9871419
28
Cangrelor Approved Phase 4 163706-06-7 9854012
29
carbamide peroxide Approved Phase 4 124-43-6
30
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
31
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
32
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
33
Mycophenolic acid Approved Phase 4 24280-93-1 446541
34
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
35
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
36
Tenecteplase Approved Phase 4 191588-94-0
37
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
38 Protective Agents Phase 4
39 Anticoagulants Phase 4
40 Heparin, Low-Molecular-Weight Phase 4
41 Antiemetics Phase 4
42 Methylprednisolone Acetate Phase 4
43 Gastrointestinal Agents Phase 4
44 Neuroprotective Agents Phase 4
45 Antineoplastic Agents, Hormonal Phase 4
46 Plasminogen Phase 4
47 Tissue Plasminogen Activator Phase 4
48 Thromboplastin Phase 4
49 Epinephryl borate Phase 4
50 Mydriatics Phase 4

Interventional clinical trials:

(show top 50) (show all 261)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
2 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
3 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
4 Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Completed NCT01927549 Phase 4
5 Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT02544594 Phase 4
6 Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine Completed NCT01367743 Phase 4 epinephrine perfusion;norepinephrine perfusion
7 Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT00491036 Phase 4
8 Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes Completed NCT00417378 Phase 4
9 Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial. Completed NCT00420030 Phase 4 Abciximab
10 Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure. Completed NCT00324766 Phase 4 levosimendan;placebo,
11 Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction. Completed NCT00257153 Phase 4
12 Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis Completed NCT00598533 Phase 4
13 Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography Completed NCT01594736 Phase 4 ORSIRO
14 Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Plexus Block, a Randomized Controlled Study Completed NCT02630290 Phase 4 Ropivacaine;Ropivacaine + Dexmedetomidine
15 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
16 ON Pump vs OFF Pump Myocardial Revascularization in High Risk Patients: a Randomized Study Completed NCT01290952 Phase 4
17 Clopidogrel Or Metoprolol in Myocardial Infarction Trial Completed NCT00222573 Phase 4 clopidogrel and metoprolol
18 Pain, Agitation and Delirium Protocol in Ventilated Patients in the Duke CICU Completed NCT02903407 Phase 4 Midazolam;Propofol;Dexmedetomidine
19 Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
20 A Randomised Trial on Early Stress Nuclear Scan for Patients Presented to the Emergency Department (ED) With Chest Pain But Non-diagnostic Electrocardiography-Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
21 CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial Completed NCT01281033 Phase 4
22 Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Completed NCT00494247 Phase 4
23 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
24 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4
25 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
26 Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment Recruiting NCT03387605 Phase 4 Ivabradine;Placebo
27 Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
28 Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock Recruiting NCT03551964 Phase 4 Cangrelor;Ticagrelor
29 Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial Recruiting NCT03549923 Phase 4 Esmolol;Standard care
30 China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction Recruiting NCT03792035 Phase 4 Tongxinluo;Placebos
31 Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive Recruiting NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
32 Intracoronary Analysis of Cardiac Allograft Vasculopathy in Comparison to Coronary Artery Disease by Means of Optical Coherence Tomography Recruiting NCT02254668 Phase 4
33 Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management Recruiting NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
34 Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH) Not yet recruiting NCT03437369 Phase 4 Ivabradine Oral Tablet
35 Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes: A Pilot Study Not yet recruiting NCT03631654 Phase 4 Ivabradine;Placebos
36 National Multicenter Randomized Trial, Comparing Two Treatments of Myocardial Infarction Complicated With Cardiogenic Shock: Standard Treatment vs Standard Treatment Plus ECLS (Extracorporeal Life Support) Terminated NCT00314847 Phase 4
37 A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI) Terminated NCT02000661 Phase 4
38 TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction Terminated NCT00257309 Phase 4 Tenecteplase + UFH (+ clopidogrel, since 01/97)
39 Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study Unknown status NCT00093301 Phase 2, Phase 3 Levosimendan;Dobutamine
40 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
41 Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction With Right Ventricular Extension: A Multicentric Randomized Controlled Trial Unknown status NCT02905760 Phase 3 Furosemide;Placebo filling;Placebo furosemide;Vascular filling
42 Impact of One Stage Compared With Multistaged PCI Complete Revascularization on Clinical Outcome in Multivessel NSTEMI Patients. Smile Trial Unknown status NCT01478984 Phase 3
43 Evaluation of N-acetylcystein on Biomarkers of Platelet Activation , Cardiac Necrosis and Coronary Reperfusion in Patients Undergoing Percutaneous Coronary Intervention Unknown status NCT01741207 Phase 3 N-acetylcystein
44 Effect of External Counter Pulsation on IschemicStroke (ECP-STROKE) Unknown status NCT03075137 Phase 3
45 Impact of Intravenous Exenatide Versus Insulin on Quality of Life in Cardiac Surgery Patients: an Ancillary Study of the ExSTRESS Phase II/III Clinical Trial Unknown status NCT02432976 Phase 2, Phase 3 Exenatide;Insulin
46 Arterial Revascularization for Coronary Bypass Surgery: A Randomized Trial Comparing the Outcome After Using LIMA + Vein Grafts Versus Total Arterial Revascularization With LIMA + RIMA + Radial Artery Grafts Unknown status NCT00159991 Phase 3
47 Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial Unknown status NCT01500369 Phase 3
48 Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients Unknown status NCT02301910 Phase 3 Recombinant staphylokinase;Tenecteplase
49 Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. Completed NCT00000552 Phase 3 thrombolytic therapy
50 Comparison of Dopamine and Norepinephrine as the First Vasopressor Agent in the Management of Shock Completed NCT00314704 Phase 3 dopamine versus norepinephrine

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Glucagon
Inamrinone
inamrinone lactate
Sources

Genetic Tests for Cardiogenic Shock

About this section
Sources

Anatomical Context for Cardiogenic Shock

About this section

MalaCards organs/tissues related to Cardiogenic Shock:

40
Heart, Kidney, Liver, Lung, Brain, Testes, Endothelial
Sources

Publications for Cardiogenic Shock

About this section

Articles related to Cardiogenic Shock:

(show top 50) (show all 10753)
# Title Authors PMID Year
1
Cardiac troponin I levels in acute pulmonary embolism. 54 61
20222345 2009
2
Impaired plasma B-type natriuretic peptide clearance in human septic shock. 54 61
18679125 2008
3
Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). 54 61
17426922 2008
4
B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. 54 61
17448415 2007
5
Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. 54 61
19758922 2005
6
Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. 54 61
15848333 2005
7
Plasma brain natriuretic peptide reflects left ventricular function during percutaneous cardiopulmonary support. 54 61
14726055 2004
8
Quantitative measurement of the novel human plasma protein, IHRP, by sandwich ELISA. 54 61
11256472 2001
9
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 54 61
10099909 1999
10
Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). 54 61
9708650 1998
11
[Factors predictive of early mortality after acute myocardial infarction]. 54 61
8953932 1996
12
Case report of a patient who survived after cardiac arrest and cardiogenic shock by anaphylactic reaction to gadolinium during magnetic resonance imaging. 61
31956385 2020
13
Clinical Presentations and Outcomes in Patients Presenting With Acute Cardiac Events and Right Bundle Branch Block. 61
31808355 2020
14
Impella RP support in refractory right ventricular failure complicating acute myocardial infarction with unsuccessful right coronary artery revascularization. 61
31866154 2020
15
Mechanical circulatory support in cardiogenic shock. 61
31895242 2020
16
Life-saving transcatheter aortic valve implantation for acute severe aortic regurgitation due to rheumatoid arthritis and complicated by cardiogenic shock. 61
31592853 2020
17
High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction. 61
31812755 2020
18
Procedural and Clinical Outcomes in Management of Bifurcational Lesions in ST Elevation Myocardial Infarction. 61
30850216 2020
19
Prognostic Factors for Survival After Extracorporeal Membrane Oxygenation for Cardiogenic Shock. 61
30864968 2020
20
Distal Embolic Protection in Impella 5.0 Explantation: Loop and Snare Technique. 61
31563488 2020
21
The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy. 61
32016789 2020
22
Outcomes of Impella CP insertion during cardiac arrest: A single center experience. 61
31891791 2020
23
Trends, Outcomes, and Predictors of Revascularization in Cardiogenic Shock. 61
31784052 2020
24
Patient care pathways in acute heart failure and their impact on in-hospital mortality, a French national prospective survey. 61
31867437 2020
25
Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in ITaly: the IMP-IT registry. 61
31422925 2020
26
Direct Bridging to Cardiac Transplantation with the Surgically Implanted Impella 5.0 Device. 61
32031274 2020
27
Percutaneous retrieval of a dislocated LAmbre left atrial appendage occluder in a canine model. 61
31919914 2020
28
Vascular complications associated with percutaneous left ventricular assist device placement: A 10-year US perspective. 61
31638737 2020
29
Differences in presentation and clinical outcomes between left or right bundle branch block and ST segment elevation in patients with acute myocardial infarction. 61
32030999 2020
30
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. 61
31302695 2020
31
Initiation of Extracorporeal Membrane Oxygenation in the Cardiac Catheterization Laboratory: The Mayo Clinic Experience. 61
31841997 2020
32
Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. 61
32040163 2020
33
Mechanical Circulatory Support in Cardiogenic Shock: Shock Team or Bust? 61
32036864 2020
34
Cardiogenic Shock: Reflections at the Crossroad Between Perfusion, Tissue Hypoxia, and Mitochondrial Function. 61
32036863 2020
35
Physiology of the Assisted Circulation in Cardiogenic Shock: A State-of-the-Art Perspective. 61
32036862 2020
36
Haemodynamic support for cardiogenic shock and high-risk PCI: what can observational data tell us? 61
32014837 2020
37
Very high levels of PSA in patients with cardiogenic shock: Report of four clinical cases. 61
31765638 2020
38
What Is the Role of Medical Therapy in Cardiogenic Shock in the Era of Mechanical Circulatory Support? 61
31924451 2020
39
High-Sensitivity Troponin T Predicts Postoperative Cardiogenic Shock Requiring Mechanical Circulatory Support in Patients With Valve Disease. 61
31162290 2020
40
Does concurrent use of intra-aortic balloon pumps improve survival in patients with cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation? 61
31652322 2020
41
A novel mortality risk score predicting intensive care mortality in cardiogenic shock patients treated with veno-arterial extracorporeal membrane oxygenation. 61
31689611 2020
42
Suppression of Superoxide-Hydrogen Peroxide Production at Site IQ of Mitochondrial Complex I Attenuates Myocardial Stunning and Improves Postcardiac Arrest Outcomes. 61
31939812 2020
43
Outcomes of cardiogenic shock complicating acute coronary syndromes. 61
32017332 2020
44
Positive Pressure Ventilation in Cardiogenic Shock: Review of the Evidence and Practical Advice for Patients With Mechanical Circulatory Support. 61
32036870 2020
45
Short, and long-term mortality among cardiac intensive care unit patients started on continuous renal replacement therapy. 61
31711002 2020
46
Transfer of Patients With Cardiogenic Shock Using Veno-Arterial Extracorporeal Membrane Oxygenation. 61
31221511 2020
47
Hyperacute graft dysfunction in an orthotopic heart transplant in the presence of non-HLA antibodies. 61
31400258 2020
48
Anticoagulation of Impella with a Bivalirudin Purge Solution. 61
32028295 2020
49
Validation of National Cardiovascular Data Registry risk models for mortality, bleeding and acute kidney injury in interventional cardiology at a German Heart Center. 61
31236693 2020
50
Longitudinal impact of temporary mechanical circulatory support on durable ventricular assist device outcomes: An IMACS registry propensity matched analysis. 61
31866174 2020
Sources

Variations for Cardiogenic Shock

About this section
Sources

Expression for Cardiogenic Shock

About this section
Search GEO for disease gene expression data for Cardiogenic Shock.
Sources

Pathways for Cardiogenic Shock

About this section

Pathways related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Folate Metabolism 1
Show member pathways
 11.46 PLAT IL6 CRP
2
amb2 Integrin signaling 1
10.84 PLAT IL6
3
Overview of nanoparticle effects 1
9.9 IL6 CRP
Sources

GO Terms for Cardiogenic Shock

About this section

Cellular components related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 PLAT NPPB IL6 CRP ADM
2 extracellular space GO:0005615 9.02 PLAT NPPB IL6 CRP ADM

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.33 IL6 CRP ADM
2 response to glucocorticoid GO:0051384 9.26 IL6 ADM
3 acute-phase response GO:0006953 8.96 IL6 CRP
4 negative regulation of lipid storage GO:0010888 8.62 IL6 CRP

Molecular functions related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.8 PLAT NPPB ADM
Sources

Sources for Cardiogenic Shock

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....